Page 22 | Certara

Publication

Modeling amyloid plaque turnover dynamics improves characterization of drug effects

Researchers modeled how amyloid plaques form and clear in Alzheimer’s disease, helping explain how treatments…

CertaraNovember 26, 2025

Guide

10 Strategic Foundations for Early Drug Development

Discover effective Early Drug Development strategies to navigate early development with confidence and clarity. Download…

CertaraNovember 26, 2025

Blog

The Stepwise PIP is Here to Stay: From Pilot Flexibility to Permanent EU Regulation

The stepwise Paediatric Investigation Plan (PIP) is a strategic, flexible route for drug developers navigating…

CertaraNovember 26, 2025

Case Study

How a Global Pharma Leader Transformed Chemical Data Management with Marvin, Chemaxon’s chemical editor

Case study on a global pharma leader upgrading to Marvin from Marvin JS and integrating…

CertaraNovember 26, 2025

Announcement

Retiring Chemicalize Pro Services, Transitioning to Modern Solutions

Retiring Chemicalize Pro on December 31st, 2025, moving to more modern solutions.

CertaraNovember 26, 2025

Blog

Certara’s Virtual Twin® QSP Models: Transforming Rare Disease Research into Clinical Insights

Certara’s Virtual Twin® QSP Models are transforming rare disease drug development, with real-world insights from…

CertaraNovember 25, 2025

Blog

The Proposed Food and Drug Administration (FDA) Development Safety Update Report (DSUR) Guidance

Learn how FDA DSUR requirements reshape drug safety reporting, align with ICH E2F, and impact…

CertaraNovember 24, 2025

Publication

Physiologically-Based Pharmacokinetic Modeling to Support Pediatric Clinical Development: An IQ Working Group Perspective on the Current Status and Challenges

The paper reviews current applications of pediatric PBPK across therapeutic areas and outlines where PBPK…

CertaraNovember 21, 2025

Poster

Early Systematic PICO Scenario Identification and Prioritization for EU HTA Joint Clinical Assessments

Discover a systematic, AI-enabled approach to early PICO scenario identification and prioritization to improve EU…

CertaraNovember 20, 2025

Conference

2025 MFDS-KCDA Annual Conference

CertaraNovember 20, 2025

Modeling amyloid plaque turnover dynamics improves characterization of drug effects

10 Strategic Foundations for Early Drug Development

The Stepwise PIP is Here to Stay: From Pilot Flexibility to Permanent EU Regulation

How a Global Pharma Leader Transformed Chemical Data Management with Marvin, Chemaxon’s chemical editor

Retiring Chemicalize Pro Services, Transitioning to Modern Solutions

Certara’s Virtual Twin® QSP Models: Transforming Rare Disease Research into Clinical Insights

The Proposed Food and Drug Administration (FDA) Development Safety Update Report (DSUR) Guidance

Physiologically-Based Pharmacokinetic Modeling to Support Pediatric Clinical Development: An IQ Working Group Perspective on the Current Status and Challenges

Early Systematic PICO Scenario Identification and Prioritization for EU HTA Joint Clinical Assessments

2025 MFDS-KCDA Annual Conference

Newsletter sign up

Quick links

Solutions

Contact